Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Select Medical Holdings Corporation (SEM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Select Medical Holdings Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Select Medical Holdings Corporation trades at $16.51 (market cap $2.05B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 19.5× Select Medical Holdings Corporation's market cap, and Select Medical Holdings Corporation pays a 1.51% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | SEM | |
|---|---|---|
Market Cap | $39.89B | $2.05B |
Sector | Health | Health |
52-Week High | $491.22 | $16.66 |
52-Week Low | $278.09 | $11.77 |
Enterprise Value | $38.15B | $5.01B |
Dividend Yield | — | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Select Medical Holdings (SEM) trades at $16.51, unchanged on the day, following the company's recent acquisition by a consortium led by Robert A. Ortenzio at $16.50 per share. The stock shows mixed technical signals with a bullish overall trend but bearish moving averages. Fundamentally, the company reported $5.45B revenue for 2025 with a 2.42% net margin, while valuation metrics appear reasonable with a P/E of 15.43 and P/S of 0.36. Recent earnings have been mixed with one beat and two misses against expectations.
The investment outlook is dominated by the completed acquisition, effectively capping upside near the current price. While fundamentals show stable operations with positive cash flow from operations, multiple law firms are investigating potential fiduciary breaches in the buyout process. Analyst sentiment is mixed with 35.7% buy ratings, but the acquisition removes typical growth catalysts. Key risks include legal challenges to the merger terms and execution risks during the ownership transition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Select Medical Holdings Corporation
Select Medical Holdings Corporation is one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States. The company's services focus on treating patients with serious illnesses, injuries, and post-acute care needs. SEM provides specialized care across various settings, aiming to help patients recover and return home.
Read more on SEM →
